A Randomized, Phase I/II Trial of Irinotecan and Temozolomide Compared to Irinotecan and Temozolomide in Combination With TPI 287 in Patients With Primary Refractory or Early Relapsed Neuroblastoma.

Trial Profile

A Randomized, Phase I/II Trial of Irinotecan and Temozolomide Compared to Irinotecan and Temozolomide in Combination With TPI 287 in Patients With Primary Refractory or Early Relapsed Neuroblastoma.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 04 Nov 2016

At a glance

  • Drugs TPI 287 (Primary) ; Irinotecan; Temozolomide
  • Indications Neuroblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Jan 2016 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov.
    • 17 Nov 2014 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
    • 16 Apr 2012 Planned end date changed from 1 Dec 2014 to 1 Dec 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top